StockNews.AI
WOK
StockNews.AI
186 days

WORK Medical Technology Group LTD Reports Financial Results for Fiscal Year 2024

1. WORK Medical's net revenue decreased 15.2% to $11.5 million in FY 2024. 2. 69.4% drop in mask sales impacted overall revenue, which was partially offset. 3. Medical device sales rose 17.7%, driven by increased marketing efforts. 4. Operating expenses surged, influencing the company's net loss of $3.5 million. 5. IPO raised $7.4 million, boosting cash reserves to $6.6 million.

33m saved
Insight
Article

FAQ

Why Bearish?

Declining revenue and net loss suggest financial instability, reminiscent of past downturns impacting stock prices.

How important is it?

Significant changes in revenue and enduring losses indicate substantial influence on stock performance.

Why Short Term?

Immediate financial indicators may affect investor sentiment until strategic plans show results.

Related Companies

CCIHABCLSHLT
, /PRNewswire/ -- WORK Medical Technology Group LTD ("WORK Medical" or the "Company") (Nasdaq: WOK), a supplier of medical devices in China, today reported its financial results for the fiscal year ended September 30, 2024. Mr. Shuang Wu, Chairman and Chief Executive Officer of WORK Medical, remarked, "We are pleased to report our Company's performance for the fiscal year ended September 30, 2024. As the lingering effects of COVID-19 gradually subside and the global business environment returns to normal, our net revenue reflects a decline primarily due to a 69.4% decrease in mask sales. We have implemented a strategic transformation to drive growth in other key revenue streams over recent years. Specifically, our sales of medical devices, excluding masks, increased by 17.7% to $9.4 million for fiscal year 2024. This, coupled with a 33.9% growth in commodity trading, has partially mitigated the decline in mask sales. To support this transformation, we made investments in marketing and promoting medical devices other than masks, which is reflected in the 31.0% rise in selling and marketing expenses. These expenditures represent strategic investments aimed at long-term growth, which, we believe will position us on a more balanced foundation for future success. Despite the challenges mentioned, our R&D expenses increased by 0.3%. Looking ahead, we plan to leverage our cash reserves to support ongoing strategic transformations. Our focus will be on driving innovation, exploring overseas opportunities, accelerating internationalization, and securing additional global orders, so as to deliver greater value to our shareholders." Fiscal Year 2024 Financial Results Net Revenue Net revenue was $11.5 million in fiscal year 2024, representing a decrease of 15.2% from $13.6 million in fiscal year 2023. The overall decrease in net revenue was mainly due to the decline in demand and unit price of masks and was offset by the increase of revenue of medical devices other than masks and commodity trading. For the Year Ended, September 30, ($ millions) 2024 2023 Masks $    1.6 $    5.1 Medical devices other than masks 9.4 8.0 Commodity trading 0.4 0.3 Others 0.1 0.2 Net revenue $   11.5 $   13.6 Revenue of sales of masks was $1.6 million in fiscal year 2024, representing a decrease of 69.4% from $5.1 million in fiscal year 2023. The decrease was mainly because (i) the demand for masks and the sales volume of masks decreased for the year ended September 30, 2024; and (ii) the Company shifted its marketing focus from masks to medical devices other than masks. Revenue of sales of medical devices other than masks was $9.4 million in fiscal year 2024, representing an increase of 17.7% from $8.0 million in fiscal year 2023. The increase was mainly attributable to the Company's decision to intensify marketing efforts for medical devices other than masks, which accordingly led to higher sales volumes. Revenue of commodity trading was $0.4 million in fiscal year 2024, representing an increase of 33.9% from $0.3 million in fiscal year 2023. The increase was mainly due to the increase of market demand and the Company's business expansion. Revenue of sales of others was $0.1 million in fiscal year 2024, representing a decrease from $0.2 million in fiscal year 2023. Cost of Revenue Cost of revenue was $8.6 million in fiscal year 2024, representing a decrease of 8.3% from $9.4 million in fiscal year 2023. The decrease in the cost of revenue was less than the decrease in net revenue, mainly because the unit cost of medical devices other than masks was relatively higher than the unit cost of masks; therefore, the increased sales of medical devices other than masks partially offset the decrease in the cost of revenue related to masks. Gross Profit Gross profit was $2.9 million in fiscal year 2024, representing a decrease of 30.8% from $4.1 million in fiscal year 2023. Gross profit margin was 24.9% in fiscal year 2024, compared to 30.5% in fiscal year 2023. The decrease of gross profit margin was primarily due to the increased sales of medical devices other than masks with relatively lower profit margin and the decreased sales of masks with relatively higher profit margin for the year ended September 30, 2024. Operating Expenses Operating expenses were $6.9 million in fiscal year 2024, which increased $3.2 million from $3.7 million in fiscal year 2023. Selling expenses were $2.1 million in fiscal year 2024, representing an increase of 31.0% from $1.6 million in fiscal year 2023. The increase was primarily due to increased marketing and promotion expenses incurred for the sales of medical devices other than masks. General and administrative expenses were $4.6 million in fiscal year 2024, representing an increase of 144.8% from $1.9 million in fiscal year 2023, which was primarily due to the increase of professional consulting fees for consulting services regarding financial reporting requirements for a U.S. public company. Research and development expenses were $0.302 million in fiscal year of 2024, representing an increase of 0.3% from $0.301 million in fiscal year 2023, which remained relatively stable. Net (Loss) Income Net loss was $3.5 million in fiscal year 2024, compared to net income of $0.06 million in fiscal year 2023. Basic and Diluted Earnings (Loss) per Share Basic and diluted loss per share was $0.27 in fiscal year 2024, compared to basic and diluted earnings per share of $0.01 in fiscal year 2023. Financial Condition As of September 30, 2024, the Company had cash and cash equivalents of $6.6 million, which increased $5.0 million from $1.6 million as of September 30, 2023. Net cash used in operating activities was $2.2 million in fiscal year 2024, compared to net cash provided by operating activities of $2.2 million in fiscal year 2023. Net cash used in investing activities was $9.1 million in fiscal year 2024, compared to $0.6 million in fiscal year 2023. Net cash provided by financing activities was $15.7 million in fiscal year 2024, compared to net cash used in financing activities of $0.7 million in fiscal year 2023. Recent Development On August 26, 2024, the Company completed its initial public offering of 2,000,000 ordinary shares at a public offering price of US$4.00 per ordinary share. The ordinary shares began trading on the Nasdaq Capital Market on August 23, 2024 under the ticker symbol "WOK." About WORK Medical Technology Group LTD WORK Medical Technology Group LTD is a supplier of medical devices that develops and manufactures Class I and II medical devices and sells Class I and II disposable medical devices through operating subsidiaries in China. The Company has a diverse product portfolio comprising 21 products, including customized and multifunctional masks and other medical consumables. All the products have been sold in 34 provincial-level administrative regions in China, with 15 of them sold in more than 30 countries worldwide. The Company has received a number of quality-related manufacturing designations and has registered 17 products with the U.S. Food and Drug Administration allowing their products to enter the U.S. market. For more information, please visit the Company's website: https://www.workmedtech.com/corporate. Forward-Looking Statements Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results, and encourages investors to read the risk factors contained in the Company's registration statement and other reports it files with the U.S. Securities and Exchange Commission before making any investment decisions regarding the Company's securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. For investor and media inquiries, please contact: WORK Medical Technology Group LTDInvestor Relations DepartmentEmail: [email protected] Ascent Investor Relations LLCTina XiaoPhone: +1-646-932-7242Email: [email protected] WORK MEDICAL TECHNOLOGY GROUP LTDCONSOLIDATED BALANCE SHEETS (In U.S. dollars, except for otherwise noted) As of September 30, 2024 2023 Assets Current assets:        Cash and cash equivalents $ 6,557,605 $ 1,596,096        Restricted cash - 41,187        Cash deposited in escrow account 400,000 -        Accounts receivable, net 1,648,797 3,332,322        Inventories, net 3,183,951 4,620,191        Amounts due from related parties 2,707,136 4,237,682        Advance to suppliers 4,697,029 3,469,819        Prepaid expenses and other current assets, net 1,632,702 4,855,381 Total current assets 20,827,220 22,152,678        Property, plant and equipment, net 11,372,485 6,626,774        Intangible assets, net 1,044,062 998,450        Right-of-use assets, net - 114,127        Deferred tax assets, net 112,916 66,872        Advance to suppliers for equipment 2,893,880 - Total non-current assets 15,423,343 7,806,223 TOTAL ASSETS $ 36,250,563 $ 29,958,901 Liabilities Current liabilities:        Short-term bank borrowings $ 13,323,643 $ 8,840,461        Accounts payable 1,497,152 3,961,827        Deferred revenue 625,326 776,210        Amount due to related parties 1,217,442 159,612        Accrued expenses and other liabilities 3,007,901 4,398,596        Lease liabilities, current - 49,560        Income tax payable 508,726 736,590 Total current liabilities 20,180,190 18,922,856        Lease liabilities, non-current - 50,130 Total non-current liabilities - 50,130 TOTAL LIABILITIES $ 20,180,190 $ 18,972,986 Shareholders' equity        Ordinary Shares (par value of $0.0005 per share; 100,000,000 shares          authorized as of September 30, 2024 and 2023; 14,591,942 and          12,500,000 shares issued and outstanding as of September 30, 2024          and 2023, respectively)* $ 7,296 $ 6,250        Subscription receivable (6,250) (6,250)        Additional paid-in capital 6,617,596 85,012        Statutory reserve 899,731 887,482        Retained earnings 6,076,018 9,580,585        Accumulated other comprehensive loss (408,465) (676,828) Total shareholders' equity 13,185,926 9,876,251 Non-controlling interests 2,884,447 1,109,664 Total equity 16,070,373 10,985,915 TOTAL LIABILITIES AND EQUITY $ 36,250,563 $ 29,958,901 * The shares and per share information are presented on a retroactive basis to reflect the reorganization and share reorganization by way of a subdivision and surrender of shares. WORK MEDICAL TECHNOLOGY GROUP LTD CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE LOSS (In U.S. dollars, except for otherwise noted) For the years endedSeptember 30, 2024 2023 2022 Net revenue from third parties $ 10,929,070 $ 12,501,615 $ 19,498,315 Net revenue from related party 577,370 1,064,336 212,975 Cost of revenues from third parties (8,346,419) (8,596,872) (15,197,213) Cost of revenue from related party (291,635) (826,095) (95,285) Gross profit 2,868,386 4,142,984 4,418,792 Operating expenses: Selling expenses (2,053,019) (1,567,385) (1,032,685) General and administrative expenses (4,558,041) (1,861,728) (2,563,879) Research and development expenses (302,511) (301,644) (183,900) Total operating expenses (6,913,571) (3,730,757) (3,780,464) Other (loss) income: Interest expense (557,571) (392,741) (352,968) Interest income 11,727 25,417 1,969 Government subsidies 346,571 74,232 1,186,641 Other income(expenses), net 578,758 (8,746) (360,409) Total other income(loss) 379,485 (301,838) 475,233 (Loss) income before income tax expense (3,665,700) 110,389 1,113,561 Income tax benefit (expense) 125,291 (47,006) (169,435) Net (loss) income $ (3,540,409) $ 63,383 $ 944,126 Net (loss) income attributable to non-controlling interest (48,091) (48,647) 78,916 Net (loss) income attributable to ordinary shareholders $ (3,492,318) $ 112,030 $ 865,210 Other comprehensive loss: Foreign currency translation adjustment 453,181 (268,068) (1,147,710) Total comprehensive loss (3,087,228) (204,685) (203,584) Total comprehensive income (loss) attributable to non-controlling interests 136,727 (80,165) (164,329) Total comprehensive loss attributable to shareholders $ (3,223,955) $ (124,520) $ (39,255) Weighted average number of Ordinary Shares Basic and Diluted* 12,705,011 12,500,000 12,500,000 Basic and diluted (loss) earnings per ordinary share (0.27) 0.01 0.07 *    The shares and per share information are presented on a retroactive basis to reflect the reorganization      and share reorganization by way of a subdivision and surrender of shares. WORK MEDICAL TECHNOLOGY GROUP LTD CONSOLIDATED STATEMENTS OF CASH FLOWS (In U.S. dollars, except for share and per share data, or otherwise noted) For the years ended September 30, 2024 2023 2022 CASH FLOWS FROM OPERATINGACTIVITIES: Net (loss) income $ (3,540,409) $ 63,383 $ 944,126 Adjustments to reconcile net loss to net cash usedin operating activities: Depreciation and amortization 1,410,452 1,603,129 3,258,267 Inventories write-down 762 18,320 (117,327) Gain (loss) on disposal of equipment 42,504 8,089 (10,871) Allowance for credit loss 262,446 149,503 1,108,999 Deferred tax benefits (46,044) (94,533) (314,008) Changes in assets and liabilities: Accounts receivable – third parties 1,815,361 (131,950) (4,234,997) Accounts receivable – related party — — 275,993 Advance to suppliers (1,061,321) 977,318 (191,774) Amount due (from) to related parties 1,775,923 (3,964,077) 743,490 Inventories 1,576,799 (400,544) 2,053,675 Operating lease liabilities (2,029) (51,755) (5,212) Prepaid expenses and other current assets 293,683 1,291,145 (194,118) Accounts payable (2,553,902) 864,585 (5,822,547) Income taxes payable (250,423) 136,508 81,428     Deferred revenue (176,969) 52,245 (751,375) Accrued expenses and other liabilities (1,524,631) 1,688,370 917,303 Net cash (used in) provided by operating activities (2,228,087) 2,209,736 (2,258,948)  CASH FLOWS FROM INVESTING ACTIVITIES:    Purchase of intangible asset (33,313) (127,913) —    Purchase of property and equipment (9,225,094) (455,391) (2,012,546)    Proceed from disposal of property and equipment 194,328 — 601,760    Cash acquired from Shanghai Saitumofei — — 63,621 Net cash used in investing activities (9,064,079) (583,304) (1,347,165) CASH FLOWS FROM FINANCINGACTIVITIES:    Proceeds from initial public offering 7,373,839 — —    Cash deposited in escrow account (400,000) — —    Contributions from non-controlling interest 2,767,032 — —    Proceeds from short-term borrowings 13,394,778 9,107,082 7,248,367 Repayments of short-term borrowings (9,369,404) (6,000,791) (7,248,367) Loans to related parties (4,574,088) (5,669,834) (9,493,121) Repayment from related parties 5,477,054 5,891,373 13,260,930 Loans to third parties (1,133,656) (2,723,935) (1,030,628) Repayment from loans to third parties 2,734,478 23,562 829,042 Payment of offering cost (613,009) (1,356,176) —       Net cash provided by (used in) financing  activities 15,657,024 (728,719) 3,566,223 Effect of exchange rate changes 555,464 (33,852) (59,819) Net increase (decrease) in cash and restricted cash 4,920,322 863,861 (99,709) Cash, cash equivalents, and restricted cash, atbeginning of year 1,637,283 773,422 873,131 Cash, cash equivalents and restricted cash, at end of year $ 6,557,605 $ 1,637,283 $ 773,422 Reconciliation to amounts on consolidatedbalance sheets: Cash and cash equivalents 6,557,605 1,596,096 731,178 Restricted cash - 41,187 42,244 Total cash, cash equivalents and restricted cash shown in the statement of cash flows 6,557,605 1,637,283 773,422 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Income taxes paid 9,973 $ 160,162 $ 340,024 Interest paid 543,753 $ 312,035 $ 312,282 SOURCE WORK Medical Technology Group LTD WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News